Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Resistell logo — Our rapid AST will save lives by finding the right antibioti...

Resistell

Our rapid AST will save lives by finding the right antibiotic on time and will reduce spreading of antibiotic resistance

Founded 2017 Switzerland Muttenz, Switzerland 26 employees Series B Total: $6.91M Medical Devices

General Information

Company Name Resistell
Founded Year 2017
Location Switzerland Muttenz, Switzerland
Employees 26
Industries Medical Devices
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Resistell. To contact Resistell, visit resistell.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Resistell compare?

A PDF of Resistell and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Resistell soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Resistell

Resistell is a Swiss-based startup founded in 2018 with a clear mission encapsulated in their slogan, "Our rapid AST will save lives by finding the right antibiotic on time and will reduce spreading of antibiotic resistance." The company aims to revolutionize antibiotic susceptibility testing with a growth-independent rapid AST method. This approach not only significantly reduces the time required for obtaining results from days to minutes but also provides crucial information on the appropriate antibiotic and its administration concentration for effective patient treatment. The latest milestone for Resistell came with a Fr.8.50M Series B investment on 20 December 2022, signaling confidence in the company's innovative solution. Notable investors participating in this round included Launchpad, Occident, The European Innovation Council, TRUMPF Venture, and Zürcher Kantonal Bank. This financing round not only provides essential capital for further development and commercialization but also serves as a validation of the potential impact of Resistell's technology in the battle against antibiotic resistance. With its groundbreaking approach, Resistell has the potential to not only save countless lives by enabling timely and accurate antibiotic prescriptions but also to contribute significantly to the global effort in reducing the spread of antibiotic resistance. This promising startup has positioned itself as a key player in the critical intersection of healthcare and technology, possibly reshaping the landscape of antibiotic susceptibility testing and treatment decisions.

Business keywords: Antibiotic resistance, Diagnostic technology, Bacterial resistance testing, Healthcare innovation, Rapid diagnosis, Treatment efficiency, Medical cost reduction, Infectious diseases, Medical technology, Antimicrobial resistance, Healthcare system improvement

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Grant Undisclosed 1
Pfizer
26 Apr 2022
Grant €2.50M 1
European Innovation Council
European Innovation Council
03 Jul 2020
Series A Fr.3.50M 5
Alpana Ventures Occident TRUMPF Venture
Alpana Ventures, Occident +3
17 Dec 2019
Grant Fr.130.00K 1
Venture Kick
Venture Kick
28 Dec 2018
Seed Round Fr.750.00K 2
Occident Hemex
Occident, Hemex
09 Dec 2018
Grant Fr.20.00K 1
Venture Kick
Venture Kick
31 May 2018
Grant Fr.10.00K 1
Venture Kick
Venture Kick
01 Feb 2018

Resistell Alternatives & Competitors

View All Alternatives
Resistell vs
Astek Diagnostics
Astek Diagnostics United States

One-hour antibiotic sensitivity testing

Non Equity Assistance
14 employees
Health Care, Medical Devices
Compare Resistell vs Astek Diagnostics
Resistell vs
EMPE Diagnostics
EMPE Diagnostics Sweden

Confirmatory precision diagnostics for tuberculosis (MDR/XDR-TB) within 3 h even at resource-limited...

Series A
27 employees
Biotechnology, Health Care
Compare Resistell vs EMPE Diagnostics
Resistell vs
Avails Medical, Inc.
Avails Medical, Inc. United States

Avails Medical, Inc. - Affordable & Rapid Antibiotic Susceptibility Testing for clinical laboratorie...

Grant
51 employees
Health Care, Medical Devices
Compare Resistell vs Avails Medical, Inc.
View all alternatives

FAQ About Resistell

Our rapid AST will save lives by finding the right antibiotic on time and will reduce spreading of antibiotic resistance
Resistell was founded in 2017.
Resistell is headquartered in Muttenz, Switzerland.
Resistell operates in Medical Devices. Its work centres on Antibiotic resistance, Diagnostic technology, Bacterial resistance testing and Healthcare innovation.
Resistell has approximately 26 employees.
Resistell has completed 7 funding rounds, raising a total of $6.91M. The latest funding stage is Series B.
Top alternatives and competitors to Resistell include Astek Diagnostics, EMPE Diagnostics, Avails Medical, Inc., UTI-lizer, Tangen Biosciences, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Resistell and Astek Diagnostics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Resistell, https://bouncewatch.com/company/resistell, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout